1stOncology™: Cancer Intelligence Service – Page 15176 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Bicycle Therapeutics and Cancer Research UK Announce Presentation at 2018 American Society of Clinical Oncology Meeting

On May 31, 2018 Cancer Research UK and Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported a poster presentation at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) held from June 1 – June 5, 2018 in Chicago, Ill (Press release, Bicycle Therapeutics, 31 31, 2018, View Source [SID1234527010]). The poster describes their ongoing phase I/IIa clinical trial of BT1718 in patients with advanced solid tumours, which is the first clinical study of a bicyclic peptide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details of the presentation, which will be given by Dr. Udai Banerji, Principal Investigator for the Phase I trial, are as follows:

A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Time: June 4, 2018, 8:00 – 11:30 a.m. CT

ABOUT BT1718
BT1718 is a first-in-class Bicycle Toxin Conjugate being developed by Bicycle Therapeutics that targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14. This target has an established role in cell invasion and metastasis, is linked to poor outcomes and is over expressed in many solid tumours. In preclinical models, BT1718 has demonstrated promising target-dependent efficacy and only a subset of the toxicities typically associated with other highly potent cancer treatments.

Cancer Research UK’s Centre for Drug Development (CDD) is sponsoring a Phase I/IIa study of BT1718 that started in February 2018 with patients currently progressing through dose escalation cohorts. The trial is co-managed by Cancer Research UK and Bicycle Therapeutics. Under the terms of the agreement, Bicycle retains the right to further advance the BT1718 program, at which point an undisclosed payment split between cash and equity, success-based milestones and royalty payments would be made to Cancer Research UK.

Xencor to Present at Upcoming Investor Conferences

On May 31, 2018 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, reported that company management will present at two upcoming conferences (Press release, Xencor, MAY 31, 2018, View Source [SID1234527009]):

Jefferies 2018 Healthcare Conference
Date: Thursday, June 7, 2018
Time: 1:30 p.m. ET
Location: New York, NY

JMP Securities Life Sciences Conference
Date: Wednesday, June 20, 2018
Time: 1:30 p.m. ET
Location: New York, NY

Live webcasts of both events will be available under "Events & Presentations" in the Investors section of the Company’s website located at View Source A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 90 days following the presentations.

TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

On May 31, 2018 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, reported that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference at 12:30 pm EDT on Friday, June 8, 2018, in New York, NY (Press release, Tracon Pharmaceuticals, MAY 31, 2018, View Source [SID1234527008]).

To access a live webcast of the presentation, please visit the "Events and Presentation" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

Rigel to Present at Jefferies 2018 Global Healthcare Conference

On May 31, 2018 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that Raul Rodriguez, the company’s president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference in New York City on Tuesday, June 5, 2018 at 10:30am EDT (Press release, Rigel, MAY 31, 2018, View Source;p=RssLanding&cat=news&id=2352484 [SID1234527005]).

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI?PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma

On May 31, 2018 Polaris Group reported that the first patient has been dosed in a phase 2 trial of ADI‑PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma, sponsored by Washington University (Press release, Polaris Pharmaceuticals, MAY 31, 2018, View Source [SID1234527003]). In addition to a global phase 2/3 study in malignant plural mesothelioma featuring ADI‑PEG 20 in combination with pemetrexed and cisplatin and a global phase 2 study in hepatocellular carcinoma featuring ADI‑PEG 20 in combination with FOLFOX, Polaris Group is currently conducting multiple phase 1 clinical trials, including ADI‑PEG 20 in combination with pembrolizumab in solid tumors, in combination with low dose cytarabine for acute myeloid leukemia in older patients, and in combination with atezolizumab, pemetrexed and cisplatin in non-small cell lung carcinoma.

"We are very excited to partner with Polaris to bring metabolic therapies to the field of rare tumors", said the lead investigator Brian Van Tine, M.D., Ph.D., Associate Professor of Medicine and Sarcoma Program Director at Barnes and Jewish Hospital, Washington University in St. Louis.

About ADI-PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI‑PEG 20.